萊姆病：新型療法、未滿足的需求與TPP洞察報告，2026年

市場概覽

• 法國萊姆病市場預計將從 2025 年的 7,000 萬美元成長到 2035 年的 1.6 億美元。
• 以下因素正在推動市場成長：
• 人們對疾病的認知不斷提高，診斷測試的準確性也日益提高。
• 持續研發新的抗感染疾病療法和疫苗
• 未來的成長取決於早期診斷、預防策略和更有效治療方法的進步。

萊姆病的新療法及對TPP的深入了解

Thelansis 發布的《萊姆病：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026》對該適應症的關鍵新興療法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

萊姆病概述

萊姆病是一種蜱傳細菌感染疾病，如果早期發現，通常可以透過短期口服抗生素治療成功治愈，因此，典型症狀的急性治療已基本成為臨床難題。然而，目前仍存在兩大挑戰。首先，有相當一部分患者即使在接受標準抗生素治療後，仍會持續出現疲勞、關節疼痛或認知障礙等症狀。其次，此病的發病機制尚未完全闡明，診斷標準和有效治療方案也尚未達成共識。此外，由於上一代疫苗已於數十年前撤出市場，因此一直缺乏有效的預防措施。不過，這項預防空白正在逐步彌補，一種新一代候選疫苗已通過重要的後期臨床試驗，並正進入法規核准階段。這將是近幾十年來首個新型萊姆病疫苗。其他輔助策略，例如使用長效抗體和標靶蜱蟲的藥物（旨在預防感染發生前的傳播）等，也處於早期研發階段。對於相關人員，萊姆病的防治標誌著從單純的急性治療轉變為真正的預防。

主要亮點

• 根據預測，德國萊姆病新發病例數將從 2025 年的 56,330 例增加到 2035 年的 57,357 例。
• 萊姆病是蜱傳細菌感染疾病最常見的一種，早期診斷對於預防長期併發症至關重要。
• 延遲治療或治療不足會導致持續的神經系統、心臟和肌肉骨骼症狀。
• 對於持續性或難治性病例，診斷和治療方法仍有顯著的未滿足需求，亟需改善。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 大公司
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 意識
• 預期用途/處理線
• 以滿足重大未滿足需求的程度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Pfizer
• ModernaTX, Inc.
• Tarsus Pharmaceuticals, Inc.
• Biocodex

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興療法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Lyme Disease Emerging Therapy and TPP Insights

Thelansis's "Lyme Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Lyme Disease Overview

Lyme disease is a tick-borne bacterial infection that, when caught early, is generally treated successfully with a short course of oral antibiotics, making acute care for typical presentations a largely solved clinical problem. The more persistent challenge lies at two edges of that success: a meaningful minority of patients continue to experience fatigue, joint pain, or cognitive symptoms even after standard antibiotic treatment; a poorly understood condition that has resisted consensus diagnosis and effective therapy, and prevention has lacked a viable tool since an earlier vaccine was withdrawn from the market decades ago. That prevention gap now appears close to closing, as a next-generation vaccine candidate has cleared a pivotal late-stage trial and is advancing toward regulatory review, marking what would be the first new Lyme vaccine in a generation. Complementary strategies, including long-acting antibody-based prophylaxis and tick-targeted medications designed to block transmission before infection occurs, are also progressing through earlier development. For stakeholders, Lyme disease shows a category pivoting from acute treatment alone toward genuine prevention.

Key Highlights

• In Germany, incident Lyme disease cases are projected to increase from 56,330 in 2025 to 57,357 by 2035.
• Lyme disease is the most common tick-borne bacterial infection, with early diagnosis being critical to prevent long-term complications.
• Delayed or inadequate treatment may lead to persistent neurological, cardiac, and musculoskeletal manifestations.
• Significant unmet need remains for improved diagnostics and therapies for persistent or difficult-to-treat disease.

Market Overview

• The France Lyme disease market is projected to grow from $70M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing disease awareness and improved diagnostic testing
• Ongoing development of novel anti-infective therapies and vaccines
• Future growth will depend on advancements in early diagnosis, preventive strategies, and more effective treatment options.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• ModernaTX, Inc.
• Tarsus Pharmaceuticals, Inc.
• Biocodex

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)